Abstract 213P
Background
Renal cell carcinoma with sarcomatoid de-differentiation (sRCC) is a highly aggressive form RCC with trials reporting a poor median OS of 5 to 12 months. Recent genomics profiling of sRCC suggest that Srcc is not a single entity but is highly influenced by the parent RCC subtype from which its shares histological characteristic. A recent meta-analysis suggests that sRCC is associated with a higher cancer specific mortality, poorer progression free and overall survival but not gender and average age. A population-based study of 879 patients taken from the SEER data showed that the 5-year DSS were 77.7%, 67.8%, 35.4%, and 3.5% for patients with stage I, II, III, and IV disease at diagnosis.
Methods
A retrospective analysis was conducted on patients diagnosed with sRCC from 1997 to 2018. Disease characteristics, treatment outcomes and adverse events were retrieved from digital medical records. Overall survival and progression free survival were estimated using Kaplan Meier method.
Results
62 patients with a diagnosis of sRCC were identified. 72% (n = 45) were males. Median age was 56 years old on diagnosis. Majority of patients were Chinese at 72%. 52%(N = 32) were metastatic on diagnosis with 18%(n = 12) were diagnosed with initially early stages(I-II). 80%(n = 47) were symptomatic from the cancer on diagnosis with at least 1 symptom of haematuria, flank pain, fever, loss of weight. Majority of the patients (n = 54) had were clear cell rcc with sarcomatoid component while the 7% (n = 5) were papillary rcc. The median overall survival for the metastatic group was 1.26 years with 53% having had VEGF inhibitors as first line treatment while about a quarter had no treatment.
Conclusions
We currently report the disease characteristics and treatment of patients diagnosed with sRCC in our tertiary cancer centre. In our study, about half of the cohort was metastatic on diagnosis with another 20% having early stage on initial diagnosis. The overall survival outcomes of this real world metastatic sRCC group is promising and appears better than prior reports. More research is needed to better understand this group of patients with poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ravindran Kanesvaran.
Funding
Has not received any funding.
Disclosure
R. Kanesvaran: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Johnson and Johnson. All other authors have declared no conflicts of interest.
Resources from the same session
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract